ijms-logo

Journal Browser

Journal Browser

Molecular Advances in Nanomedicine

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Nanoscience".

Deadline for manuscript submissions: closed (15 April 2024) | Viewed by 629

Special Issue Editor


E-Mail Website
Guest Editor
Department of Chemical Sciences, University of Catania, 95125 Catania, Italy
Interests: smart materials; nanomaterials; hybrid biointerfaces; theranostics; nanomedicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The continuous development of smart nanomaterials and nanotechnology in recent decades enabled significant progress in the use of biocompatible multifunctional nanoparticles (NPs) in advanced drug delivery, imaging, and biosensing for the treatment of various illnesses, including cancer, diabetes, neurodegenerative and infectious diseases. However, NPs are still at the early stages of clinical translation, with many challenges remaining regarding various unmet medical needs. Advances in NP design and fabrication are, therefore, very promising in the attempt ot make decisive breakthrough in the state-of-the-art in nanomedicine and precision medicine, which is crucial to achieving a controlled mechanism of drug administration and delivery, a convenient crossing of physiological barriers, and enhanced therapeutic efficacy. This Special Issue will focus on the recent and most promising approaches to the fabrication of advanced nanomedicines. Suitable topics include, but are not limited to: smart, stimuli-responsive nanomaterials for advanced drug delivery and theranostics; bioinspired chemistry and peptidomimetic approaches to nanomedicine; mechanisms of action of nanoparticles in the treatment of various diseases, including cancer, wound healing, CNS disorders, infections, and others; versatile nanoparticles for multimodal theranostic platforms; nanomedicine and nanotoxicity; sustainable multidisciplinary strategies for nanoparticle synthesis, characterization, and their applications with regard to nanomedicine.

Dr. Cristina Satriano
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanomaterials
  • advanced drug delivery
  • bioimaging
  • biosensing
  • theranostics
  • sustainability science for nanomedicine
  • multifunctional nanoparticles

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

18 pages, 1741 KiB  
Review
Current Advancements in Anti-Cancer Chimeric Antigen Receptor T Cell Immunotherapy and How Nanotechnology May Change the Game
by Kimberly S. Ku, Jie Tang, Yuan Chen and Yihui Shi
Int. J. Mol. Sci. 2024, 25(10), 5361; https://doi.org/10.3390/ijms25105361 - 14 May 2024
Viewed by 270
Abstract
Chimeric antigen receptor (CAR)-T cell immunotherapy represents a cutting-edge advancement in the landscape of cancer treatment. This innovative therapy has shown exceptional promise in targeting and eradicating malignant tumors, specifically leukemias and lymphomas. However, despite its groundbreaking successes, (CAR)-T cell therapy is not [...] Read more.
Chimeric antigen receptor (CAR)-T cell immunotherapy represents a cutting-edge advancement in the landscape of cancer treatment. This innovative therapy has shown exceptional promise in targeting and eradicating malignant tumors, specifically leukemias and lymphomas. However, despite its groundbreaking successes, (CAR)-T cell therapy is not without its challenges. These challenges, particularly pronounced in the treatment of solid tumors, include but are not limited to, the selection of appropriate tumor antigens, managing therapy-related toxicity, overcoming T-cell exhaustion, and addressing the substantial financial costs associated with treatment. Nanomedicine, an interdisciplinary field that merges nanotechnology with medical science, offers novel strategies that could potentially address these limitations. Its application in cancer treatment has already led to significant advancements, including improved specificity in drug targeting, advancements in cancer diagnostics, enhanced imaging techniques, and strategies for long-term cancer prevention. The integration of nanomedicine with (CAR)-T cell therapy could revolutionize the treatment landscape by enhancing the delivery of genes in (CAR)-T cell engineering, reducing systemic toxicity, and alleviating the immunosuppressive effects within the tumor microenvironment. This review aims to explore how far (CAR)-T cell immunotherapy has come alone, and how nanomedicine could strengthen it into the future. Additionally, the review will examine strategies to limit the off-target effects and systemic toxicity associated with (CAR)-T cell therapy, potentially enhancing patient tolerance and treatment outcomes. Full article
(This article belongs to the Special Issue Molecular Advances in Nanomedicine)
Show Figures

Figure 1

Back to TopTop